


HILOTHERAPY®

The world's first processor-controlled hand/foot cooling to prevent CIPN.

Simple. Compatible. Highly effective.

The effective cooling treatment.



The problem:

Diagnosis cancer - chemotherapie - CIPN

Despite innovative targeted therapy approaches, chemotherapy is still one of the most important therapeutic components in the treatment of cancer. It contributes to improving the long-term prognosis of oncological patients, but also causes side effects.

Chemotherapy-induced polyneuropathy [CIPN] is a frequent complication of many antineoplastic system therapies.

The danger: CIPN ≥ Grade 2

- Therapy postponement
- Dose reduction
- Termination of therapy
- Deterioration of the long-term prognosis (outcome)
- Deterioration of quality of life for many years and often irreversible

Studies show: high incidence rates.



The incidence rate of CIPN (grades 1-3) is significantly higher than previously thought, at 74.4% (Blackley et al, 2019).

- 33% grade 2/3 toxicities with three weeks of Taxol administration [Seidmann et al., JCO 2008]
- 51% grade 2/3 toxicities with weekly paclitaxel administration [Seidmann et al., JC0 2008]
- 27% ≥ grade 2 toxicities with paclitaxel weekly (Sparano et al., N Engl J Med 2008)



HILOTHERM ChemoCare® CIPN

The effective cooling treatment.

The solution:

HILOTHERAPY®
The effective cooling treatment

For the prevention of Polyneuropathie (CIPN) and Hand-Foot-Syndrom (HFS).



HILOTHERM ChemoCare® CIPN

Controlled cooling of the extremities during chemotherapy.

Advantages:

- + Processor-controlled thermal process accurate to the degree
- + constant cooling of the hands and feet with moderate coldness
- Oxygen demand of the tissue, metabolism as well as blood circulation are reduced
- reduced uptake of cytotoxic substances into the nerve endings Reduction of nerve damage
- + Pain receptors are positively influenced pain relief

The HILOTHERM ChemoCare®-device is equipped with special hand/foot cuffs and enables constant cooling of the extremities.

Simple. Compatible. Highly effective.



Efficacy:

Our data prove the prophylactic effectiveness of HILOTHERAPY®.

Without prophylactic HILOTHERAPY® 90% of all patients inside develop symptoms of CIPN and Hand-Foot-Syndrom (Grade 1 - 3) – 50% of them severe (Grade 2/3).



+ 93% Grade 0-1

Used as prophylaxis, 93% of patients remain pain-free and without limiting symptoms (CIPN < grade 1).

No impairment in everyday life.

Fewer symptoms

Even starting HILOTHERAPY® later in treatment will have an effect: the progression of severe CIPN is halted and it will prevent existing problems getting worse.

+ Faster symptom-free

4 weeks after last chemotherapy:

96% of all patients with prophylactic HILOTHERAPY® show only grade 0 - 1 symptoms.

Sustainable results:

12 months after the end of chemotherapy, 98% of all patients are still symptom-free [CIPN < grade 1].

I am an oral surgeon loss of sensitivity in my fingers
would have resulted in me
not being able to practice
my profession.
Thanks to HILOTHERAPY®
I have not developed
any CIPN symptoms.

Patient Hannelore Sch.

Get the best results when starting with the first chemotherapy treatment:

The earlier you start HILOTHERAPY[®], the better. Grade 2 and 3 toxicities can be be greatly reduced or avoided.

Cross your heart.
You try to do everything possible to reduce side effects of chemotherapy and better quality of life for your patients.

Also with HILOTHERM®

HILOTHERM Chemo Care® CIA

Controlled scalp cooling to avoid or reduce chemotherapy-induced alopecia / hair loss (CIA)



Hilotherm GmbH Wittumweg 38 | D - 88260 Argenbühl-Eisenharz Tel.: 07566/91199 | Fax: 07566/9415116 info@hilotherm.com | www.hilotherm.com

Follow us on Social Media







